In November 2021, CR Pharmaceutical fully complete✨d the acquisition of Boya Bio-pharmaceutical, with a shareholding ratio of 28.86% and a voting right of 40.01%, realizing a strategic development in the field of ﷽;blood products.
In September 2021, CR Jiangzhong acquired a 51% stake in H✤ays Pharma Limited, adding high-quality varieties to its original gastroenterology products.
In July 2021, CR Pharmaceutical acquired a 10% stake in Immunotech Biopharm Ltd. for strategic development in the field of cellular immunotherapy.﷽&nbs♒p;
In February 2021, CR Double-Crane acquired a 33.3% stake in Zhejiang Peptites Biotech Co., Ltd. by means of capital increase, establis♚hing its presence in the peptide field.
The class I innovative drug NIP046 developed by CR P🌌ဣharmaceutical was approved for clinical trial targeting rheumatoid arthritis indications.
The class I innovative drug NIP292 obtained ෴the Orphan Drug Designation (ODD) issued by the Food and Drug Administration (FDA) for the treatmen♋t of idiopathic pulmonary fibrosis (IPF).
CR Double-♐Crane acquired 38.75% of the stakeꦕ of Dongying Tiandong Pharmaceutical Co., Ltd.
CR Pharmaceutical completed the reorganization of CR Jiangzhong. By then, Jiangxi Jiangzhong Pharmaceutical (Group) Co., Ltd. (Jiangzhong Group) was renamed China Resources 𝔉Jiangzhong Pharmaceutical Group Co., Ltd🌄. (CR Jiangzhong) and was listed as a first-level profit center in CR Pharmaceutical’s management sequence.
CR Sanjiu, CR Double-Crane, 💙and Dong-E-E-Jiao👍 were officially included in the FTSE Russell Global Index.
The class I innovative druﷺg NIP292 for the treatment of idiopathic pulmonary fibrosis (IPF) obtained the approval of FDA for Phase I clinical trial.
CR Double-Crane held a meeting for celebrating the company’s 80th anniversary of its foundation in Beiji𒉰ng.
CR signed a strategic cooperation agreement with the People’s Government of Jiangxi for the reorganization of Jiangzh🍌ong Group. CR Pharmaceutical acqui💜red or subscribed over 51% stake of Jiangzhong Group equity through cash or assets.
CR Pharmaceutical was selected as a constituent stock of the Hang Seng Corporate Sustainability B🃏enchmark Index.
CR Sanjiu an𒁃d Dong-E-E-Jiao 🦩were listed in the MSCI Emerging Market Index.
CR Double-Cr🔯ane acquired Hunan Xiangzhong Pharmaceutical Co., Ltd.
CR Pharmaceutical was listed as a constituent stock in the Hang Seng Composite LargeCap Index, the Hang Seng Mainland Healthcare Index, the Hang Seng Healthcare Index, the Hang Seng China-Affiliated Corporations Index, the Hang Seng China (Hong Kong-ꦬlisted) 100 Index, the FTSE Global Equity Inde🍨x Series (Large Cap), the FTSE All-World Index Series, the FTSE Global All Cap Index, and the MSCI China Index.
CR Sanjiu acquired 65% of the equity of Jilin Jinfukang Pharmace💃utical Co., Ltd. and 65% of the equity of Shandong Shenghai Health Products Co., Ltd. CR Double-Crane acquired 100% of the equity of Hainan Zhong Hua Lian He Pharmaceutical. Co., Ltd.
We completed the acquisition of 100% interest in CR Pharmaceutical Retail Group which wholly owned CR Care, a company principally engaged in pharmacy business in China and Hong Kong.
CR Pharmaceutical Holdings was awarded the “Top 10 PRC Pharmaceutical Group of 2015 (国家健康安全行业内内工厂集困前十)” at the ChemPharm Annual Summit 2015(2015国家耐腐蚀制药厂行业内内第四季度论坛会).
Our Company ranked No.4 among the “Top 100 Enterprises in the PRC Pharmaceutical Industry of 2013 (2014年度全球国药产业五百强公司”.CR Pharmaceutical Holdings was awarded the “Top 10 PRC Pharmaceutical Group of 2014 (华人健康安全互联网行业中集团公司网站前十强)” at the ChemPharm Annual Summit 2014 (2014华人有机化学化工互联网行业中年中高峰会).The Beijing Pharmaceutical Group Industry-University-Research Alliance (南京制药团体产学联盟名字) led by our Company under the Eleventh-Five Year Plan was successfully completed and accepted.
BEID Fund became a shareholder of our Company.The total assets and revenue of our Group for the year respectively exceeded HK$100 billion for the first time.
CR Pharmaceutical Commercial became a wholly-owned subsidiary of our Company.We acquired the remaining 52.72% interest in CR Zizhu to further develop our product portfolio and enhance our market penetration.Pharmaceutical R&D Center became our wholly-owned subsidiary.We established the Health Institute of China Resources University (55世纪
高校健康保健高校) in June 2012.
We acquired the remaining 50% interest in Beijing Pharmaceutical, and thereafter Beijing Pharmaceutical became a wholly-owned subsidiary of our company.Beijing Pharmaceutical investment became a Share holder of our Company.We successfully completed 11 mergers and acquisitions in Beijing, Jiangsu, Henan and other provinces, which further developed our core businesses and enhanced our presence in the pharmaceutical market in China.
Our company entered into a strategic cooperation agreement with the China Academy of Medical Sciences (在我国临床完美院) to strengthen the research and development capabilities of our Group.We acquired 50% interest in Beijing Pharmaceutical from CRC.CR Double-Crane became our non-wholly owned subsidiary following the completion of acquisition of 50% interest in Beijing Pharmaceutical.
We acquired 56.62% interest in CR Dong-E from CRC, thereby controlling 23.14% interest in Dong-E-E-Jiao, a company listed on the Shenzhen Stock Exchange and principally engaged in the manufacturing of E Jiao (donkey-hide gelatin) products. We completed the acquisition of 66.98% interest in CR Sanjiu, a company listed on the Shenzhen Stock Exchange and principally engaged in the manufacturing and sale of OTC drugs and Chinese prescription medicine.
Our Company was incorporated in Hong Kong.
CRC was engaged in the restructuring of China Worldbest, and acquired 50% interest in Beijing Pharmaceutical.
CRC set up CR Done-E with Liaocheng SASAC (the State-Owned Assets Supervision and Administration Commission of the State Council).
Our controlling shareholder, China Resources Holdings, was incorporated in Hong Kong.
China Resources Company (55世纪
品牌) started to export medicines and medical devices to mainland China.
Liow & Company (综合行) was renamed as China Resources Company (55世纪
有限公司)
Liow & Company (结合行), the predecessor of China Resources Holdings, our controlling shareholder, was founded.
